The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

NOW the sun is out, your SPF should be too. Did you know we are recommended to use two shot glasses worth of suncream to cover our body? It might seem excessive, but no patch should be left ...

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

For the new AI, researchers gathered data from an eczema tracking app called Atopiyo that is popular in Japan. More than 28,000 users have shared more than 57,000 symptom photos and personal comments ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...